참고문헌
- Aoki, K., Kurooka, M., Chen, J. J., Petryniak, J., Nabel, E. G., and Nabel, G. J., Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity. Nat. Immunol., 2, 333-337 (2001) https://doi.org/10.1038/86336
- Bazzoni, F. and Beutler, B., The tumor necrosis factor ligand and receptor families. N. Engl. J. Med., 334, 1717-1725 (1996) https://doi.org/10.1056/NEJM199606273342607
- Braun, M. Y, Lowin, B., French, L., Acha-Orbea, H., and Tschopp, J., Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J. Exp. Med., 183, 657-661 (1996) https://doi.org/10.1084/jem.183.2.657
- Date, T., Mochizuki. S., Belanger, A. J., Yamakawa, M., Luo, Z., Vincent, K. A., Cheng, S. H., Gregory, R. J., and Jiang, C., Differential effects of membrane and soluble Fas ligand on cardiomyocytes: role in ischemia/reperfusion injury. J. Mol. Cell Cardiol., 35, 811-821 (2003) https://doi.org/10.1016/S0022-2828(03)00139-1
- Frankel, B., Longo S.L., and Canute, G. W, Soluble Fas-ligand (sFasL) in human astrocytoma cyst fluid is cytotoxic to Tcells: another potential means of immune evasion. J. Neurooncol., 48, 21-26 (2000) https://doi.org/10.1023/A:1006473800589
- Hasegawa, H., Matsumiya, S., Uchiyama, M., Kurokawa, T., Inouye, Y .Y., Kasai, R, Ishibashi, S., and Yamasaki, K., Inhibitory effect of some triterpenoid saponins on glucose transport in tumor cells and its application to in vitro cytotoxic and antiviral activities. Planta Med., 60, 240-243 (1995a) https://doi.org/10.1055/s-2006-959467
- Hasegawa, H., Sung, J. H., Matsumiya,S., Uchiyama, M., Inouye, Y., Kasai R., and Yamasaki, K., Reversal of daunomycin and vinblastine resistance in multidrug-resistant P388 leukemia in vitro through enhanced cytotoxicity by triterpenoids. Planta Med., 61, 409-413 (1995b) https://doi.org/10.1055/s-2006-958126
- Hasegawa, H., Sung, J. H., Matsumiya, S., and Uchiyama, M., Main ginseng saponin metabolites formed by intestinal bacteria. Planta Med., 62, 453-457 (1996) https://doi.org/10.1055/s-2006-957938
- Kagi, D., Vignaux, F., Ledermann, B., Burki, K., Depraetere, V., Natata, S., Hengartner, H., and Golstein, P, Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science, 265, 528-530 (1994) https://doi.org/10.1126/science.7518614
- Kayagaki, N., Kawasaki, A., Ebata, T., Ohmoto, H., Ikeda, S., Inoue, S., Yoshino, S., Okumura, K., and Yagita, H., Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med., 182, 1777-1783 (1995) https://doi.org/10.1084/jem.182.6.1777
- Lee, B. H., Lee, S. J., Hur, J. H., Lee, S., Sung, J. H., Huh, J. D., and Moon, C. K., In vitro antigenotoxic activity of novel ginseng saponin metabolites formed by intestinal bacteria. Planta Med., 64, 500-503 (1998) https://doi.org/10.1055/s-2006-957501
- Lee, S. H., Shin, M. S., Lee, H. S., Bae, J. H., Lee, H. K., Kim, H. S., Kim, S. Y, Jang, J. J., Joo, M., Kang, Y. K., Park, W. S., Park, J. Y., Oh, R. R., Han, S. Y., Lee, J. H., Kim, S. H., Lee J. Y., and Yoo, N. J., Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum. Pathol., 32, 250-256 (2001) https://doi.org/10.1053/hupa.2001.22769
- Lee, S. J., Sung, J. H., Lee, S. J., Moon, C. K. and Lee, B. H., Antitumor activity of a novel ginseng saponin metabolite in human pulmonary adenocarcinoma cells resistant to cisplatin. Cancer Lett. , 144,39-43 (1999) https://doi.org/10.1016/S0304-3835(99)00188-3
- Lee, S. J., Ko, W. G., Kim, J. H., Sung, J. H., Lee, S. J., Moon C. K., and Lee, B. H., Induction of apoptosis by a novel intestinal metabolite of ginseng saponin via cytochrome c-mediated activation of caspase-3 protease. Biochem. Pharmacol., 60, 677-685 (2000) https://doi.org/10.1016/S0006-2952(00)00362-2
- Medema, J. P., Scaffidi, C., Kischkel, F. C., Shevchenko, A., Mann, M., Krammer, P H., and Peter, M. E., FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J., 16,2794-2804 (1997) https://doi.org/10.1093/emboj/16.10.2794
- Mitsiades, N., Poulaki, V, Kotoula, V, Leone, A., and Tsokos, M., Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am. J. Pathol., 153, 1947-1956 (1998) https://doi.org/10.1016/S0002-9440(10)65708-2
- Nagata, S., Fas ligand-induced apoptosis. Ann. Rev. Genet., 33,29-55 (1999) https://doi.org/10.1146/annurev.genet.33.1.29
- Nelson, D. P., Setser, E., Hall, D. G., Schwartz, S. M., Hewitt, T, Klevitsky, R., Osinska, H., Bellgrau, D., Duke, R. C., and Robbins, J., Proinflammatory consequences of transgenic fas ligand expression in the heart. J. Clin. Invest., 105, 1199-1208 (2000) https://doi.org/10.1172/JCI8212
- Niehans, G. A., Brunner, T. S., Frizelle, S. P., Liston, J. C., Salerno, C. T, Knapp, D. J., Green D. R., and Kratzke, R. A., Human lung carcinomas express Fas ligand. Cancer Res., 57,1007-1012 (1997)
- OConnell, J., OSullivan, G. C., Collins, J. K., and Shanahan, F., The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med., 184, 1075-1082 (1996) https://doi.org/10.1084/jem.184.3.1075
- Oh, S. H. and Lee, B. H., A ginseng saponin metabolite-induced apoptosis in HepG2 cells involves a mitochondria-mediated pathway and its downstream caspase-8 activation and Bid cleavage. Toxicol. Appl. Pharmacol., 194,221-229 (2004) https://doi.org/10.1016/j.taap.2003.09.011
- Oyaizu, N., Kayagaki, N., Yagita, H., Pahwa, S., and Ikawa, Y, Requirement of cell-cell contact I the induction of Jurkat T cell apoptosis: the membrane-anchored but not soluble form of FasL can trigger anti-CD3-induced apoptosis in Jurkat T cells. Biochem. Biophys. Res. Commun., 238, 670-675 (1997) https://doi.org/10.1006/bbrc.1997.7357
- Perez, C., Albert, I., DeFay, K., Zachariades, N., Gooding, L., and Kriegler, M., A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell, 63,251-258 (1990) https://doi.org/10.1016/0092-8674(90)90158-B
- Poulaki. V. Mitsiades. C. S.. and Mitsiades. N.. The role of Fas and FasL as mediators of anticancer chemotherapy. Drug Resist. Updat., 4, 233-242 (2001) https://doi.org/10.1054/drup.2001.0210
- Schneider, P, Holler, N., Bodmer, J. L., Hahne, M., Frei, K., Fontana, A., and Tschopp, J., Conversion of membranebound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med., 187,1205-1213 (1998) https://doi.org/10.1084/jem.187.8.1205
- Shiraki, K., Tsuji, N., Shioda, T, Isseibacher, K. J., and Takahashi, H., Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. U.S.A., 94, 6420-6425 (1997) https://doi.org/10.1073/pnas.94.12.6420
- Strand, S., Hofmann, W. J., Hug, H., Muller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H., and Galle, P. R., Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat. Med., 21, 361-1366 (1996)
- Tanaka, M., Itai, T., Adachi, M., and Nagata, S., Downregulation of Fas ligand by shedding. Nat. Med., 4, 31-36 (1998) https://doi.org/10.1038/nm0198-031
- von Haefen, C., Wieder, T., Essmann, F., Schulze-Osthoff, K., Dorken, B., and Daniel, P. T., Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop. Oncogene, 22, 2236-2247 (2003) https://doi.org/10.1038/sj.onc.1206280
- Wajant, H., The Fas signaling pathway: more than a paradigm. Science, 296,1635-1636 (2002) https://doi.org/10.1126/science.1071553
- Wollert, K. C., Heineke, J., Westermann, J., Ludde, M., Fiedler, B., Zierhut, W., Laurent, D., Bauer, M. K., Schulze-Osthoff, K., and Drexler, H., The cardiac Fas (APO-1/CD95) Receptor/Fas ligand system: relation to diastolic wall stress in volume-overload hypertrophy in vivo and activation of the transcription factor AP-1 in cardiac myocytes. Circulation, 101, 1172-1178 (2000) https://doi.org/10.1161/01.CIR.101.10.1172